Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial

Supporters

PJ

Patrick Joyce

+

Add your support

Preprint Server

Topics

Medicine

Immunology

Public Health

Pharmacology

Covid-19

DOI

10.1101/2020.07.31.20161216

License

CC-BY-NC-ND

Other Formats

PDF